Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.

Human pathology - 1 Feb 2015

Rakheja Dinesh, Fuda Franklin, Vandergriff Travis, Boriack Richard, Medeiros Bruno C, Frankel Arthur E, Chen Weina

Abstract excerpt

Blastic plasmacytoid dendritic cell neoplasm is an exceedingly rare hematologic malignancy derived from the precursors of plasmacytoid dendritic cells. Mutations in isocitrate dehydrogenase (IDH) 1 and 2 genes have been discovered in a range of neoplasms including glioma, acute myeloid leukemia, chondrosarcoma, and intrahepatic cholangiocarcinoma. Mutant IDH acquires neomorphic enzymatic activity to generate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Dendritic Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH2 gene

Share to Glutarates

Share to Hematologic Neoplasms

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 25481493
DOI: 10.1016/j.humpath.2014.10.013

Genes

IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.PMID 25481493Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System NeoplasmsSemantic proximity Read ↗

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Semantic proximity Read ↗

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Semantic proximity Read ↗

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.Semantic proximity Read ↗

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d ‐2‐hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcomaSemantic proximity Read ↗

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.Semantic proximity Read ↗

Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.